International Journal For Multidisciplinary Research

E-ISSN: 2582-2160   •   Impact Factor: 9.24

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Call for Paper Volume 6 Issue 6 November-December 2024 Submit your research before last 3 days of December to publish your research paper in the issue of November-December.
Submit Research Paper Join as a Reviewer

Plagiarism is checked by the leading plagiarism checker TurnItIn

Call for Paper

Volume 6 Issue 6
November-December 2024

Submit your research paper

Indexing Partners
Academia Advanced Sciences Index Bielefeld Academic Search Engine CiteSeer DRJI Google Scholar Independent Search Engine & Directory Network ISI (International Scientific Indexing) Issuu Mendeley Research Networks
RefSeek ResearcherId - Thomson Reuters ResearchGate Scirus Scribd Semantic Scholar UTeM - Universiti Teknikal Malaysia Melaka Wiki for Call for Papers WorldCat Zenodo

Capivasertib:the Breakthrough Cancer Treatment of the Decade's

Author(s) Gaikwad Dipti Ramesh, Dube Shubhada B., Kawade Rajendra M
Country India
Abstract Capivasertib (TRUQAP), a novel oral AKT inhibitor, targets the PI3K/AKT/mTOR pathway to overcome tumour resistance in advanced breast cancer.Capivasertib has a unique pyrrolopyrimidine derivative structure and is a highly strong ATP-competitive inhibitor of all three AKT isoforms (AKT1, AKT2, and AKT3).This article provides a thorough examination of capivasertib's synthesis, mechanisms of action, physical and chemical properties, and preclinical and clinical efficacy.Its advantages over existing treatments, possible adverse effects, and prospective use in combination therapy are examined.We also examine possible future paths for managing resistance, optimising the therapeutic advantages of capivasertib, and selecting the best patients using biomarkers.Preclinical research has demonstrated the potential of capivasertib in conjunction with endocrine therapy and anti-HER2 drugs. Its clinical importance is highlighted by the FDA's recent approval of TRUQAP in conjunction with Faslodex in November 2023 for advanced HR-positive and HER2-negative breast cancer.
Keywords Capivasertib, AKT Inhibitor, Breast cancer, TRUQAP
Field Medical / Pharmacy
Published In Volume 6, Issue 6, November-December 2024
Published On 2024-12-07
Cite This Capivasertib:the Breakthrough Cancer Treatment of the Decade's - Gaikwad Dipti Ramesh, Dube Shubhada B., Kawade Rajendra M - IJFMR Volume 6, Issue 6, November-December 2024. DOI 10.36948/ijfmr.2024.v06i06.31595
DOI https://doi.org/10.36948/ijfmr.2024.v06i06.31595
Short DOI https://doi.org/g8t3kz
View / Download PDF File

Share this



E-ISSN 2582-2160
CrossRef

CrossRef DOI is assigned to each research paper published in our journal.

IJFMR DOI prefix is
10.36948/ijfmr

Downloads
Research Paper Format Copyright Permission Form and Undertaking Form Cover Page Vol 6 Isu 6Cover Page Vol 6 Isu 5Cover Page Vol 6 Isu 4

All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.

CC-BY-SA Open Access

About IJFMR
Fees & Payment
Current Issue
Publication Archive 		Submit Research Paper
Track Submission Status
Publication Guidelines
Publication Ethics
Peer Review & Plagiarism 		Join as a Reviewer
Editors & Reviewers
Reviewer Referral Program
Get Reviewer Membership Certi. 		Website/Journal Policies
Usage Policy
Content Policies
Privacy Policy
Contact Us +91-9898-5948-55 editor@ijfmr.com